AstraZeneca's Etcamah Receives Accelerated FDA Approval for Specific Metastatic Breast Cancer

The FDA has granted accelerated approval to AstraZeneca's oral therapy, Etcamah (camizestrant), for first-line treatment of adult patients with specific ER+, HER2- metastatic breast cancer featuring ESR1 mutations. This decision, which allows its use with a CDK4/6 inhibitor, reversed a prior advisory panel's recommendation against approval, providing a new treatment option for this patient group.